RxDoctor Payments Data

Michael Thompson, MD

Orthopaedic Surgery · Omaha, NENPI 1154337251

Payments from drug & device makers

What this record shows

This record is dominated by education: $3,819 of the $5,805 with a category attached, or 65.8%. 8 manufacturers reported payments, led by Arthrex at 41.6% of the total. Reporting peaked in 2019 at $2,955 and has fallen 94.0% since, to $178 in 2025.

$5,805in general payments, 2019–2025

Across 39 payments — averaging $148.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arthrex$2K
  • Stryker$2K
  • Conetic Solutions, Inc.$1K
  • RSW Medical Company, Inc.$479
  • Amgen$28
  • Biocomposites Inc$24
  • plus $35 from 2 others

What the payments were for

  • Travel & lodging$71812%
  • Food & beverage$1,26922%
  • Education$3,81966%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Arthrex7$2,418
Stryker22$1,553
Conetic Solutions, Inc.4$1,268
RSW Medical Company, Inc.1$479
Amgen2$28
Biocomposites Inc1$24
Novartis1$18
KCI USA, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,805 in reported general payments places this provider in the 65th percentile of 155 orthopaedic surgery providers in Nebraska.

See all orthopaedic surgery providers in Nebraska

Medicare billing

Part B allowed, 2024
$97,764
Medicare patients
321
Services billed
1,031

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Meloxicam103$529
Prednisone13$24

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →